Revenue

3 Months Ended

Mar. 31, 2023

Revenue From Contract With Customer [Abstract]

Revenue

Note 3. Revenue

The Company disaggregates revenue by the following four customer types:

•Pharma tests and services includes sales of testing services and data analytics for clinical trials and research to pharmaceutical companies in support of their drug development programs. Individual contracts typically contemplate a single project and involve a wide range of tests and analytics deliverables from the Company that are suitable for each particular project.

•Enterprise sales includes sales of tumor profiling and diagnostic tests directly to other businesses as an input to their products. The Company is typically contracted to deliver a limited number of tests and analytics deliverables, but in high volume over time, and may offer tiered pricing. Revenue from the Company's partnership with Natera to provide advanced tumor analysis for use in Natera's MRD test makes up substantially all of the revenue in this category.

•Population sequencing includes sales of genomic sequencing services and data analytics to support large-scale genetic research programs. The Company is typically contracted to deliver a genomic test and provide data that can be used for analysis across a large volume of samples. All of the revenue within this category is from the Company's partnership with the VA MVP.

•Other includes sales of genomic tests and analytics to universities and non-profits.

The following table presents the Company’s revenue disaggregated by customer type (in thousands):

	Three Months Ended March 31,
	2023		2022
Pharma tests and services	$	6,333	$	7,562
Enterprise sales		9,458		4,116
Population sequencing		3,005		3,501
Other		64		48
Total revenue	$	18,860	$	15,227

Revenue from countries outside of the United States, based on the billing addresses of customers, represented approximately 13% and 18% of the Company’s revenue for the three months ended March 31, 2023 and 2022, respectively.

Contract Assets and Liabilities

Contract assets as of March 31, 2023 and December 31, 2022 were immaterial.

Amounts collected in advance of services being provided are deferred as contract liabilities in the condensed consolidated balance sheets. The associated revenue is recognized, and the contract liability is reduced, as the contracted services are subsequently performed. The balance of contract liabilities was $6.3 million (of which $3.7 million is included within "Other long-term liabilities") and $1.3 million as of March 31, 2023 and December 31, 2022, respectively. As of March 31, 2023, amounts related to unsatisfied services under contracts with an original expected duration of more than one year was $5 million. The Company expects to recognize approximately $1.3 million of this amount throughout the next 12 months and the remainder thereafter. Revenue recognized that was included in the contract liability balance at the beginning of each reporting period was immaterial for the three months ended March 31, 2023, and was $2.5 million for the three months ended March 31, 2022.